Arca
Skip to content

Epstein-barr virus (ebv) infection

Drug research and approvals for epstein-barr virus (ebv) infection: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 161 studies of epstein-barr virus (ebv) infection are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 161
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 161 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Mar 21, 2024A randomized phase II study of nivolumab versus nivolumab and bms-986016 (relatlimab) as maintenance treatment after first-line treatment with…RELATLIMAB (BMS-986016) / NIVOLUMAB (BMS-936558)NRG ONCOLOGYPending
Dec 2, 2021An open-label, multicenter phase 1b/2 study of nanatinostat and valganciclovir in patients with advanced epstein-barr virus-positive (ebv+) solid tumors and in…NANATINOSTAT (VRX-3996)/ VALGANCICLOVIR/ PEMBROLIZUMABVIRACTA THERAPEUTICS INC.Closed
Jun 23, 2021An open-label, phase 2 trial of nanatinostat in combination with valganciclovir in patients with epstein-barr virus-positive (ebv+) relapsed/refractory…NANATINOSTAT/ VALGANCICLOVIR/ GANCICLOVIRVIRACTA THERAPEUTICS INC.Closed
Apr 16, 2020A phase I/ii open-label study of the safety and efficacy of epstein-barr virus specific t-cell lines for the treatment of ebv infection or ebv-related…EBV-TCL-01CHU SAINTE JUSTINEPending
Sep 3, 2015A phase I/ii open-label study of the safety and efficacy of epstein-barr virus specific t-cell lines for the treatment of ebv infection or ebv-related…ANTI-EBV T-CELL LINESHOPITAL MAISONNEUVE ROSEMONTOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Nov 24, 2021nanatinostat and valganciclovirTreatment of Epstein Barr Virus-positive diffuse large B-cell lymphoma, not otherwise specified (EBV+ DLBCL, NOS)Epirare TherapeuticsDesignated

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Dec 16, 2022Ebvallotabelecleucel · orphanPierre Fabre MedicamentEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.